文献速递心力衰竭与心肌病

恩格列净对射血分数降低和保留的心衰患者运动能力和症状的影响

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
PubMed 文献 · Eur Heart J · 2021-01-01

EMPIRIAL-Reduced和EMPIRIAL-Preserved两项试验分别纳入射血分数降低(≤40%,N=312)和保留(>40%,N=315)的心衰患者,随机接受恩格列净10 mg或安慰剂治疗12周。主要终点6分钟步行试验距离变化在两组均无统计学显著性,关键次要终点KCCQ-TSS和CHQ-SAS呼吸困难评分变化亦无显著性。恩格列净耐受性良好,安全性与此前报道一致。

要点

  • 恩格列净10 mg治疗12周未显著改善HFrEF或HFpEF患者的6分钟步行距离。
  • KCCQ-TSS和CHQ-SAS呼吸困难评分变化无统计学意义。
  • HFrEF探索性分析中KCCQ-TSS应答率、淤血评分和利尿剂使用有改善,需进一步验证。

核心结论

  • 两项试验的主要终点均为中性,恩格列净未显著改善心衰患者运动能力。
  • 恩格列净在伴或不伴2型糖尿病的心衰患者中耐受性良好,安全性与此前报道一致。
  • HFrEF探索性分析中观察到假设生成性的次要终点改善。

研究设计与样本

  • EMPIRIAL-Reduced和EMPIRIAL-Preserved两项随机对照试验。
  • HFrEF患者射血分数≤40%,N=312;HFpEF患者射血分数>40%,N=315。
  • 患者随机接受恩格列净10 mg或安慰剂治疗12周。
  • 主要终点为第12周6分钟步行试验距离变化。

主要发现

  • 第12周6MWTD中位差值(恩格列净vs安慰剂)在EMPIRIAL-Reduced为-4.0米(95%CI -16.0至6.0;P=0.42)。
  • 第12周6MWTD中位差值在EMPIRIAL-Preserved为4.0米(95%CI -5.0至13.0;P=0.37)。
  • KCCQ-TSS和CHQ-SAS呼吸困难评分变化无统计学显著性。
  • HFrEF探索性分析中KCCQ-TSS应答率、淤血评分和利尿剂使用有改善。

关键数值与推荐

  • HFrEF定义为射血分数≤40%,HFpEF定义为射血分数>40%。
  • 恩格列净剂量为10 mg每日一次,疗程12周。
  • 主要终点非显著后,所有次要终点均视为探索性。

临床怎么用

  • 恩格列净10 mg在伴或不伴2型糖尿病的心衰患者中耐受性良好。
  • 本研究未显示恩格列净12周内改善运动能力,不应据此扩展适应症。
  • HFrEF患者中探索性症状改善需进一步研究验证。

局限性

  • 主要终点为中性,次要终点均为探索性,结论需谨慎解读。
  • 研究持续时间较短(12周),长期效果未知。
  • 探索性分析结果仅为假设生成性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms In patients with chronic heArt faiLure) trials evaluated the effects of empagliflozin on exercise ability and patient-reported outcomes in heart failure (HF) with reduced and preserved ejection fraction (EF), with and without type 2 diabetes (T2D), reporting, for the first time, the effects of sodium-glucose co-transporter-2 inhibition in HF with preserved EF (HFpEF). METHODS AND RESULTS: HF patients with reduced EF (HFrEF) (≤40%, N = 312, EMPERIAL-Reduced) or preserved EF (>40%, N = 315, EMPERIAL-Preserved), with and without T2D, were randomized to empagliflozin 10 mg or placebo for 12 weeks. The primary endpoint was 6-minute walk test distance (6MWTD) change to Week 12. Key secondary endpoints included Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) and Chronic Heart Failure Questionnaire Self-Administered Standardized format (CHQ-SAS) dyspnoea score. 6MWTD median (95% confidence interval) differences, empagliflozin vs. placebo, at Week 12 were -4.0 m (-16.0, 6.0; P = 0.42) and 4.0 m (-5.0, 13.0; P = 0.37) in EMPERIAL-Reduced and EMPERIAL-Preserved, respectively. As the primary endpoint was non-significant, all secondary endpoints were considered exploratory. Changes in KCCQ-TSS and CHQ-SAS dyspnoea score were non-significant. Improvements with empagliflozin in exploratory pre-specified analyses of KCCQ-TSS responder rates, congestion score, and diuretic use in EMPERIAL-Reduced are hypothesis generating. Empagliflozin adverse events were consistent with those previously reported. CONCLUSION: The primary outcome for both trials was neutral. Empagliflozin was well tolerated in HF patients, with and without T2D, with a safety profile consistent with that previously reported in T2D. Hypothesis-generating improvements in exploratory analyses of secondary endpoints with empagliflozin in HFrEF were observed.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Abraham WT, Lindenfeld J, Ponikowski P, et al. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. Eur Heart J. 2021. PMID: 33351892. doi:10.1093/eurheartj/ehaa943

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。